| Popis: |
Background Abnormal expression of cuproptosis-related regulators is closely related to the development of various cancers. However, the role of cuproptosis-related SLC31A1 (solid carrier family 31 member 1) gene, as a high-affinity copper transporter, in the prognosis and immunotherapy of multiple different cancers remains unclear.Methods Based on the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases, the expression level of SLC31A1 was analyzed in tumors and normal tissues, and the survival value of SLC31A1 was evaluated by Cox regression analysis. Then, we explored the relationship between SLC31A1 expression and genetic alterations, DNA methylation, and immune cell infiltration. And the biological function of SLC31A1 in pan-cancer was further clarified by Gene Set Enrichment Analysis (GSEA). Additionally, in colon adenocarcinoma (COAD), we deeply explored the relationship between SLC31A1 expression and clinicopathological stages, immune infiltration types, RNAss, DNAss, and tumor microenvironment scores, and the specific biological process of SLC31A1 was investigated through GO enrichment analysis.Results The expression level of SLC31A1 varied considerably with cancers, and its high expression had significant prognostic value in LIHC, KIRC, THYM, UCS, ACC, LGG, MESO, BLCA, TGCT, KICH, COAD, STAD, PCPG, and BRCA. SLC31A1 expression was significantly correlated with genetic alterations, DNA methylation, and immune cell infiltration. GSEA further indicated that SLC31A1 was mainly related to immune regulation signals in various cancers. In COAD, SLC31A1 expression was remarkably related to RNAss and immune scores, and GO analysis revealed that SLC31A1 was mainly associated with DNA and RNA replication, activity, and binding.Conclusion Our research first systematically revealed the potential value of SLC31A1 in prognosis and immunotherapy in multiple cancers, especially in COAD, suggesting that it will become a new target in the prognosis and treatment of cancers. |
